Quantcast
Last updated on April 24, 2014 at 11:09 EDT

Latest MAQUET Cardiovascular LLC Stories

2013-05-21 08:28:51

-- TigerPaw® System II to launch in the United States this month and in Europe in June 2013 -- WAYNE, N.J., May 21, 2013 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has acquired LAAx Inc., a privately held company that has developed a unique mechanical occlusion device called the TigerPaw(®) System II ("TigerPaw II"). When implanted, TigerPaw II safely and effectively occludes the left atrial appendage...

2013-04-11 08:28:35

-- Device Expands MAQUET's Portfolio of Hemostasis Devices -- WAYNE, N.J., April 11, 2013 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and European CE mark approval for its new AIR-BAND(TM) Radial Compression Device. Indicated to assist hemostasis of the radial artery after a transradial procedure, the device is designed to...

2012-10-29 03:20:54

WAYNE, N.J., Oct. 29, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE mark approval for its new SENSATION PLUS(®) 7.5Fr. 40cc intra-aortic balloon (IAB) catheter. This new larger-volume, fiber-optic IAB catheter will allow clinicians to provide a higher-efficacy IAB counterpulsation therapy "at the speed of light" to smaller...

2012-08-26 22:21:59

MUNICH and WAYNE, N.J., Aug. 27, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, the market leader in intra-aortic balloon counterpulsation therapy, today announced 30-day results from the large, randomized, multicenter IABP- SHOCK II ("SHOCK II") clinical trial in patients with acute myocardial infarction (AMI) who were in cardiogenic shock and undergoing early revascularization. The findings showed that use of intra-aortic balloon counterpulsation (IABC) therapy was associated with...

2012-06-18 22:21:16

WAYNE, N.J., June 19, 2012 /PRNewswire/ -- MAQUET Cardiovascular, LLC announced today that it has received CE mark for its INTERGARD SYNERGY vascular graft. This graft represents the next generation in antimicrobial grafts combining the well-known antimicrobial properties of silver acetate and triclosan. The INTERGARD SYNERGY graft will be commercially available immediately within countries that recognize the CE mark. Vascular graft infection, although rare, is one of the most serious...

2012-05-14 02:27:40

MAHWAH, N.J., May 14, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new MEGA 7.5Fr. 30cc and 40cc intra-aortic balloon (IAB) catheters. These new, larger volume catheters will allow clinicians to provide patients with greater hemodynamic support, regardless of their height. "The MEGA family of catheters represents a true...

2011-11-10 14:21:00

MAHWAH, N.J., Nov. 10, 2011 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced U.S. Food & Drug Administration (FDA) 510(k) clearance and CE mark today at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco for its new CARDIOSAVE intra-aortic balloon pump (IABP). CARDIOSAVE is expected to be commercially available in the United States in January 2012. The new CARDIOSAVE IABP incorporates a...

2010-09-22 07:00:00

WAYNE, N.J., Sept. 22 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced enrollment of the first patient in the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) trial which is designed to assess patient outcomes using a standardized, best practices approach in endoscopic vessel harvesting (EVH) for coronary artery bypass graft surgery (CABG) compared with...

2010-07-01 07:00:00

WAYNE, N.J., July 1 /PRNewswire/ -- MAQUET Cardiovascular LLC today announced that it will become the exclusive United States distributor of the INTERGARD family of vascular grafts effective October 1, 2010, when its current distribution agreement with W.L. Gore & Associates, Inc. (Gore) expires. Currently, MAQUET distributes the INTERGARD product line outside of the United States in a number of markets around the world. The addition of the INTERGARD grafts will further strengthen...

2010-06-02 07:00:00

WAYNE, N.J., June 2 /PRNewswire/ -- MAQUET Cardiovascular LLC today announced that its QUADROX-iD Pediatric Diffusion Membrane Oxygenator received 510(k) marketing clearance from the U.S. Food and Drug Administration for use in an extracorporeal perfusion system for pediatric patients up to six hours. "The QUADROX-iD Pediatric Oxygenator provides a long-awaited membrane lung specifically for infants and children," said Robert H. Bartlett, M.D., professor emeritus of surgery at the...